APA (7th ed.) Citation

J, G., S, D. M., MM, H., MB, M. A. R., XY, Z., P, J., . . . AD, J. (2022). An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma. Science translational medicine, 14(667), eabn7824. https://doi.org/10.1126/scitranslmed.abn7824

Chicago Style (17th ed.) Citation

J, Goh, et al. "An Ex Vivo Platform to Guide Drug Combination Treatment in Relapsed/refractory Lymphoma." Science Translational Medicine 14, no. 667 (2022): eabn7824. https://doi.org/10.1126/scitranslmed.abn7824.

MLA (9th ed.) Citation

J, Goh, et al. "An Ex Vivo Platform to Guide Drug Combination Treatment in Relapsed/refractory Lymphoma." Science Translational Medicine, vol. 14, no. 667, 2022, p. eabn7824, https://doi.org/10.1126/scitranslmed.abn7824.